At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 18, 2026 at 16:00 ET
ProKidney reported financial results for 2025, highlighting a reduction in net loss to $151.6 million from $163.3 million in 2024, driven by lower R&D and G&A expenses. The company maintains a strong clinical trajectory with FDA alignment on an accelerated approval pathway for rilparencel based on eGFR slope, and completed enrollment in its Phase 3 PROACT 1 trial is expected by mid-2026, with pivotal data readout anticipated in Q2 2027. Cash reserves totaled $270.0 million at year-end, sufficient to fund operations into mid-2027.
- Net loss before noncontrolling interest decreased to $151.6 million in 2025 from $163.3 million in 2024.
- R&D expenses declined to $114.1 million (from $127.7M) due to completion of prior trials, partially offset by increased costs in the ongoing PROACT 1 study.
- G&A expenses fell to $51.8 million (from $56.1M), driven by lower impairment and equity compensation charges.
- Cash, cash equivalents, and marketable securities totaled $270.0 million as of December 31, 2025, down from $358.3 million in 2024.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access